Sunstone Life Science Fund II portfolio company Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, has announced the completion of enrolment for its lead program within Niemann-Pick type C disease. Niemann-Pick type C disease (NPC) is one of several fatal lysosomal storage diseases and is affecting around 1 in 150,000 newborns. Although symptom onset and progression is highly variable, NPC is most often diagnosed in childhood and adolescence. Impaired breakdown and recycling of lipids in cells of affected individuals leads to malfunction and demise of cells in the brain and other organs, which results in seizures, progressive loss of muscle control and intellectual capacity.
Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company which in the US and Canada operates as EMD Serono, and Pfizer Inc. (NYSE: PFE) to evaluate avelumab*, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. VXM01 is an investigational oral T-cell immunotherapy designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials – one in glioblastoma and one in metastatic colorectal cancer.
* Avelumab is under clinical investigation for treatment of glioblastoma and metastatic colorectal cancer and has not been demonstrated to be safe and effective for these indications. There is no guarantee that avelumab will be approved for glioblastoma and metastatic colorectal cancer by any health authority worldwide.
Sunstone Life Science Fund III portfolio company Rigontec, the leader in RIG-I targeting RNA therapeutics, has announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. RGT100 targets the retinoic acid-inducible gene I (RIG-I) pathway, one of the most essential pathways in the innate immune system to induce both immediate and long-term anti-tumor immunity.
Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data for three of its programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 being held in Washington, DC, USA, April 1-5.
Sunstone LSV Fund II portfolio company Orphazyme ApS today announced the successful completion of a EUR 14 million financing round. Two new investors, LSP and the ALS Investment Fund joins the investor syndicate comprising Sunstone Capital, Kurma Partners, Idinvest Partners, Novo A/S and Aescap Venture.